HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lumify Reaches Canada As Consumer Health Leads Sales In Bausch + Lomb's Debut Quarter

Executive Summary

Lumify sales grew reported 21% to brand-record $35m in Q2, Bausch + Lomb’s first quarter since separating from Bausch Health through an IPO in May.

You may also be interested in...

Consumer Health Brands Pull Their Weight For Bausch + Lomb To Be ‘Non-Pharma’ Company

Canadian reports Lumify eye, PreserVision, Ocuvite and other OTC drug or supplement brands account for 67% of $646m in vision care business total sales, which was well above half Q2 total revenues of $1.04bn, up 10%.

With ‘Roadmap To Accelerate Growth,’ Saunders Quick Out Of Gate In Return To Bausch + Lomb

“Multi-year plan with three phases, all with measurable, clear objectives” starts with “rewire company for optimal performance” before moving to “innovate and execute” and then to “accelerate growth,” CEO says.

Bausch Health's Securities Litigation Casts Shadow Over B+L's Future As Independent Firm

For all B+L has going for it, including consumer health eye health and vision care products as its sales driver, it could be stymied by investors alleging Bausch Health conducted fraudulent conveyance by spinning out B+L through an IPO in 2022.

Related Content

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts